MedTrace Logo

Theophylline for Low Adenosine Syncope

NCT03803215 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2021-01-20

No results posted yet for this study

Summary

The study aims at assessing that theophylline is effective in patients with no prodromes, normal heart and with low values of plasmatic adenosine compared with a propensity-score matched untreated control population who have received an implantable cardiac monitor (ICM) for diagnosis of unexplained or atypical reflex syncope.

Conditions

  • Syncope

Interventions

DRUG

Theophylline

Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose

Sponsors & Collaborators

  • Gruppo Italiano Multidisciplinare per lo Studio della Sincope

    collaborator OTHER

  • Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella

    lead OTHER

Principal Investigators

  • Michele Brignole, MD · Department of Cardiology, Ospedali del Tigullio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-11
Primary Completion
2020-11-30
Completion
2020-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03803215 on ClinicalTrials.gov